Home/Healthcare/Biotechnology/Global Parkinson's Disease Emerging Therapies Market

Global Parkinson's Disease Emerging Therapies Market - Strategic Insights and Forecasts (2026-2035)

Market Size, Share, Forecasts and Trends Analysis By Therapy Type (Disease-Modifying Therapies, Gene Therapies, Cell Therapies, Neuroprotective Therapies, Alpha-Synuclein Targeting Therapies, LRRK2 Targeting Therapies, GBA Targeting Therapies, Neuroinflammation Targeting Therapies), By Molecule Class (Small Molecules, Monoclonal Antibodies, Gene Therapies, Cell Therapies, RNA-Based Therapies, Peptide-Based Therapies), By Route of Administration (Oral, Intravenous, Subcutaneous, Intrathecal, Intracerebral), By Clinical Development Stage (Discovery, Preclinical, Phase I, Phase II, Phase III, Regulatory Review), and Geography

Market Size in 2026
USD 0.69 billion
Market Size in 2035
USD 1.63 billion
CAGR
10.0%
Study Period
2021-2035
$3,950
Single User License
Access Full Insights
Download Free Sample
Report OverviewSegmentationTable of ContentsCustomize Report

Request Customization

Tell us your specific requirements and we will customize this report for you.

📞

Your data is secure. We do not share information with any third party.

Navigate

Need Assistance?

Our research team is available to answer your questions.

Contact Us
Report IDKSI-008780
PublishedJun 2026
Pages165
FormatPDF, Excel, PPT, Dashboard
Frequently Asked Questions

The global Parkinson’s disease emerging therapies market is projected to grow from USD 0.69 billion in 2026 to USD 1.63 billion by 2035, registering a CAGR of 10.0% during the forecast period.

Gene therapies are being developed to restore dopamine production, improve neuronal survival, and modify disease-related pathways through long-term genetic expression using viral vector technologies.

Precision medicine approaches use genetic profiling and biomarkers to identify specific patient populations that may respond better to targeted therapies. This is improving patient selection and increasing therapeutic differentiation.

Major challenges include long clinical development timelines, complex disease biology, lack of validated surrogate biomarkers, difficulties demonstrating disease-modifying effects, and stringent regulatory requirements for advanced therapies.

North America leads the market due to advanced neuroscience research infrastructure, strong biotechnology investment, extensive clinical trial activity, and supportive regulatory frameworks. Europe and Asia Pacific are also expanding rapidly.

Need data specifically for your business?Request Custom Research →

Trusted by the world's leading organizations

Weber Shandwick
veolia
Tri
tls
TeamViewer
GE Healthcare
Intel
Proctor and Gamble
ABB
Elkem
Defense Logistics Agency
Amazon